Macrolide treatment of Non-Eosinophilic Asthma

Phase 3

Recruiting

• Conditions: Asthma; Respiratory - Asthma

• Registration Number: ACTRN12605000318684
• Lead Sponsor: Hunter New England Area Health Service

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

Symptomatic stable asthma, airway hyperresponsiveness and or bronchodilator response.

Exclusion Criteria

Hypersensitivity to Macrolides, Other Respiratory Disease, Taking antihistamine medication, Pregnancy, Breast Feeding, Oral Corticosteroid use in past month, Antibiotic use in past month.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IL-8 concentations in sputum supernatant[Assessed at randomisation and at the end of the treatment.];MMP-9 concentations in sputum supernatant[Assessed at randomisation and at the end of the treatment.]

Secondary Outcome Measures

Name	Time	Method
FEV1% predicted[Assessed at randomisation and at the end of treatment.];Short acting beta agonist use[Assessed at randomisation and at the end of treatment.];Asthma Control Score[Assessed at randomisation and at the end of treatment.];Quality of Life[Assessed at randomisation and at the end of treatment.]